Internal Medicine, Hematology & Oncology · Montgomery, AL
NPI
1740578905
Since 2011
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
3
Medicare group memberships
Hospitals
5
Hospital affiliations
300 Saint Lukes Dr
Montgomery, AL, 36117
Phone (334) 273-8877
Groups this clinician bills Medicare through
Medicare paid, 2024
$250K
16,749 services
Medicare patients, 2024
90
Average age 73
Drug cost, 2024
$3.2M
861 prescriptions
Company payments, 2025
$233
From 7 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Astrid Belalcazar was code 99213 (office e&m - established), 59 times for 34 patients. In total Astrid Belalcazar billed 16,749 services in 78 codes, and Medicare paid $250K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-06-24.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Office | 59 | 34 | $58.72 | $3,465 |
| 96372 Injection Administration | Office | 54 | 17 | $9.10 | $491 |
| 99214 Office E&M - Established | Office | 43 | 30 | $86.13 | $3,703 |
| 96365 Intravenous Infusion, Hydration | Office | 17 | 11 | $37.90 | $644 |
By year: 2022 $208K for 40,092 services; 2023 $368K for 31,142 services; 2024 $250K for 16,749 services.
Lab tests billed to Medicare, 2023
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 61 | 37 | $6.57 | $401 |
Medicare prescription drug claims, 2024
In 2024, the drug Astrid Belalcazar prescribed most often to Medicare patients was Letrozole, with 60 prescriptions and refills. In total Astrid Belalcazar wrote 861 Medicare prescriptions that cost $3.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Letrozole Generic | 60 | 133 | 17 | $1,549 |
| Procrit Epoetin Alfa | 56 | 56 | 14 | $56K |
| Xgeva Denosumab | 36 | 44 | 11 | $115K |
| Keytruda Pembrolizumab | 31 | 31 | Under 11 | $343K |
| Bortezomib Generic | 26 | 27 | Under 11 | $38K |
| Revlimid Lenalidomide | 25 | 25 | Under 11 | $551K |
| Anastrozole Generic | 25 | 71 | Under 11 | $731 |
| Docetaxel Generic | 25 | 25 | Under 11 | $17K |
| Prednisone Generic | 25 | 25 | Under 11 | $112 |
| Fosaprepitant Dimeglumine Generic | 24 | 24 | Under 11 | $3,372 |
| Eliquis Apixaban | 23 | 33 | Under 11 | $19K |
| Octagam Immun Globg(Igg)/Malt/Iga Ov50 | 22 | 22 | Under 11 | $281K |
| Trazimera Trastuzumab-Qyyp | 22 | 22 | Under 11 | $95K |
| Lupron Depot Leuprolide Acetate | 19 | 57 | Under 11 | $117K |
| Palonosetron Hcl Generic | 18 | 18 | Under 11 | $2,247 |
Brand drugs: 387 claims; generic drugs: 474 claims; opioid claims: 25.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Astrid Belalcazar $233 ($233 in general payments such as food, travel and fees) from 7 companies. The largest payer was Pfizer Inc. with $62.02.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.